Hepatocellular Carcinoma: Primary and Secondary Prophylaxis as well as Medical Therapy;Hepatozelluläres Karzinom: Primär- und Sekundärprophylaxe sowie medikamentöse Therapie

Chirurgische Gastroenterologie mit Interdisziplinaren Gesprachen

Volumn 19, Issue 3, 2003, Pages 247-252

  Fleig, W E ^a   Lesske, J ^a  

^a MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

Author keywords

Hepatocellular carcinoma: prophylaxis, immunization, treatment

Indexed keywords

ALCOHOL; ANTIFIBROTIC AGENT; ANTINEOPLASTIC AGENT; CANCER VACCINE; ESTROGEN RECEPTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IODINATED POPPYSEED OIL; IODINE 131; MEGESTROL; POLYPRENOIC ACID; PRAVASTATIN; RECOMBINANT ALPHA INTERFERON; THYMOSTIMULIN;

ALCOHOL ABUSE; CANCER CHEMOTHERAPY; CANCER PREVENTION; CHRONIC HEPATITIS; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG EFFICACY; DRUG TOLERABILITY; ENVIRONMENTAL FACTOR; GENETIC DISORDER; HEMOCHROMATOSIS; HUMAN; IMMUNIZATION; IMMUNOMODULATION; LIVER CELL CARCINOMA; LIVER FUNCTION; LIVER METASTASIS; REVIEW;

EID: 0842299508     PISSN: 01779990     EISSN: None     Source Type: Journal    
DOI: 10.1159/000074010     Document Type: Review

References (30)

1. Caselmann WH, Blum H, Fleig WE, Huppert PE, Ramadori G, Schirrmacher P, Sauerbruch T: Leitlinien der Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten zur Diagnostik und Therapie des hepatozellulären Karzinoms. Z Gastroenterol 1999;37:353-365.
2. Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, Liang DC, Shau WY, Chen DS: Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 1977;336:1855-1859.
3. Chen CJ, Wang LY, Lu SN, Wu MH, You SL, Zhang YJ, Wang LW, Santella RM: Elevated aflatoxin exposure and increased risk of hepatocellular carcinoma. Hepatology 1996;24:38-42.
4. Niederau C, Heintges T, Lange S, Goldmann G, Niederau CM, Mohr L, Haussinger D. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996;334:1422-1427.
5. Jäckel E, Cornberg M, Wedemayer H, Sanantonio T, Mayer J, Zankel M, Pastore G, Dietrich M, Trautwein C, Manns MP, for the German Acute Hepatitis C Therapy Group: Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 2001;345:1452-1457.
6. Camma C, Giunta M, Andreone P, Craxi A: Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: An evidence-based approach. J Hepatol 2001;34:593-602.
7. Beutler E, Felitti VJ, Koziol JA, Ho NJ, Gelbart T: Penetrance of 845G_A (C282Y) HFE hereditary hemochromatosis mutation in the USA. Lancet 2002;359:211-218.
8. Sakaida I, Hironaka K, Okita K: Prevention of hepatocarcinogenesis by fibrosuppression; in Okita K (ed): Progress of Hepatocellular Carcinoma Treatment. Tokyo, Springer, 2000, pp 76-85.
9. Pascale RM, Simile MM, De Miglio MR, Feo F: Chemoprevention of hepatocarcinogenesis: S-adenosyl-L-methionine. Alcohol 2002;27:193-198.
10. Oka H, Yamamoto S, Kuroki T, Harihara S, Marumo T, Kim SR, Monna T, Kobayashi K, Tango T: Prospective study of chemoprevention of hepatocellular carcinoma with Sho-saiko-to(TJ-9). Cancer 1995;176:743-749.
11. Saikaida, Matsumura Y, Akiyama S, Hayashi K, Ishige A, Okita K: Herbal medicine Sho-saiko-to(TJ-9) prevents liver fibrosis and enzyme-altered lesions in rat liver cirrhosis induced by choline-deficient L-amino acid defined diet. J Hepatol 1998;29:298-306.
12. Muto Y, Moriwaki H, Ninomiya M, Adachi S, Saito A, Takasaki KT, Tanaka T, Tsurumi K, Okuno M, Tomita E, Nakamura T, Kojima T: Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group. N Engl J Med 1996;334:1561-1567.
13. Shimoda M, Bando T, Nagata T, Shirosaki I, Sakamoto T, Tsukada K: Prophylactic chemolipiodolization for postoperative hepatoma patients. Hepatogastroenterology 2001;48:493-497.
14. Lai CL, Wu PC, Chan GC, Lok AS, Lin HJ: Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized clinical trial. Cancer 1988;62:479-483.
15. O'Reilly EM, Stuart KE, Sanz-Altamira PM, Schwartz GK, Steger CM, Raeburn L, Kemeny NE, Kelsen DP, Saltz LB : A phase II study of irinotecan in patients with advanced hepatocellular carcinoma. Cancer 2001;91:101-105.
16. Kubicka S, Rudolph KL, Tietze MK, Lorenz M, Manns M: Phase II study of systemic gemcitabine chemotherapy for advanced unresectable hepatobiliary carcinomas. Hepatogastroenterology 2001;48:783-789.
17. Boucher E, Corbinais S, Brissot P, Boudjema K, Raoul JL: Treatment of hepatocellular carcinoma (HCC) with systemic chemotherapy combining epirubicin, cisplatinum and infusional 5-flourouracil (ECF regimen). Cancer Chemother Pharmacol 2002;50:305-308.
18. Leung TW, Patt YZ, Lau WY, Ho SK, Yu SC, Chan AT, Mok TS, Yeo W, Liew CT, Leung NW, Tang AM, Johnson PJ: Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin Cancer Res 1999;5:1676-1681.
19. Leung T, Tang A, Zee B, Yu S, Lai P, Lau W, Johnson P: Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy. Cancer 2002;94:421-427.
20. Farinati F, De Maria N, Fornasiero A, Salvagnini M, Fagiuoli S, Chiaramonte M, Naccarato R: Prospective controlled trial with antiestrogen drug tamoxifen in patients with unresectable hepatocellular carcinoma. Dig Dis Sci 1992;37:659-662.
21. Perrone F, Gallo C, Daniele B, Gaeta GB, Izzo F, Capuano G, Adinolfi LE, Mazzanti R, Farinati F, Elba S, Piai G, Calandra M, Stanzione M, Mattera D, Aiello A, De Sio I, Castiglione F, Russo M, Persico M, Felder M, Manghisi OG, De Maio E, Di Maio M, Pignata S, for the Cancer of Liver Italian Program (CLIP) Investigators: Tamoxifen in the treatment of hepatocellular carcinoma: 5-year results of the CLIP-1 multicentre randomised controlled trial. Curr Pharm Des 2002;8:1013-1019
22. Liu CL, Fan ST, Ng IO, Lo CM, Poon RT, Wong J: Treatment of advanced hepatocellular carcinoma with tamoxifen and the correlation with expression of hormon receptors: A prospective randomised study. Am J Gastroenterol 2000;95:218-222.
23. Chow PKH, Tai BC, Tan CK, Machin D, Win KM, Johnson PJ, Soo KC, for the Asia-Pacific Hepatocellular Carcinoma Trials Group: High dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: A multicenter randomized controlled trial. Hepatology 2002;36:1221-1226.
24. Villa E, Ferretti I, Grottola A, Buttafoco P, del Buono MG, Giannini F, Manno M, Bertani H, Dugani A, Manenti F: Hormonal therapy with megestrol in inoperable hepatocellular carcinoma characterized by variant oestrogen receptors. Br J Cancer 2001;84:881-885.
25. Grimaldi C, Bleiberg H, Gay F, Messner M, Rougier P, Kok TC, Cirera L, Cervantes A, De Greve J, Paillot B, Buset M, Nitti D, Sahmoud T, Duez N, Wils J: Evaluation of antiandrogen therapy in unresectable hepatocellular carcinoma: Results of a European Organization for Research and Treatment of Cancer multicentric double-blind trial. J Clin Oncol 1998;16:411-417.
26. Kouroumalis E, Skordilis P, Thermos K, Vasilaki A, Moschandrea J, Manousos ON: Treatment of hepatocellular carcinoma with octreotide: A randomised controlled study. Gut 1998;42:442-447.
27. Yuen MF, Poon RTP, Lai CL, Fan ST, Lo CM, Wong KW, Wong WM, Wong BCY: A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma. Hepatology 2002;36:687-691.
28. Llovet JM, Sala M, Castells L, Suarez Y, Vilana R, Bianchi L, Ayuso C, Vargas V, Rodes J, Bruix J: Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. Hepatology 2000;31:54-58.
29. Palmieri G, Biondi E, Morabito A, Rea A, Gravina A, Bianco AR: Thymostimulin treatment of hepatocellular carcinoma on liver cirrhosis. Int J Oncol 1996;8:827-832.
30. Kawata S, Yamasaki E, Nagase T, Inui Y, Iito N, Matsuda Y, Inada M, Tamura S, Noda S, Imai Y, Matsuzawa Y: Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. Br J Cancer 2001;84:886-891.